High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin

International Journal of Clinical Oncology

Volumn 16, Issue 3, 2011, Pages 244-249

  Kidera, Yasuhiro ^a,b   Satoh, Taroh ^b   Ueda, Shinya ^b   Okamoto, Wataru ^b   Okamoto, Isamu ^b   Fumita, Soichi ^b   Yonesaka, Kimio ^b   Hayashi, Hidetoshi ^b   Makimura, Chihiro ^b   Okamoto, Kunio ^b   Kiyota, Hidemi ^b   Tsurutani, Junji ^b   Miyazaki, Masaki ^b   Yoshinaga, Masahiro ^b   Fujiwara, Kimiko ^b   Yamazoe, Yuzuru ^b   Moriyama, Kenzo ^b   Tsubaki, Masanobu ^a   Chiba, Yasutaka ^b   Nishida, Shozo ^a   Nakagawa, Kazuhiko ^b   more..

^a KINKI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; FOLFOX; Hypersensitivity reaction; Oxaliplatin; Premedication

Indexed keywords

ANTIHISTAMINIC AGENT; BEVACIZUMAB; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; FLUOROURACIL; FOLINIC ACID; GRANISETRON; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; COMPRESSION FRACTURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SOMNOLENCE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT PLANNING;

ADENOCARCINOMA; ANTI-ALLERGIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COLORECTAL NEOPLASMS; DESENSITIZATION, IMMUNOLOGIC; DEXAMETHASONE; DRUG HYPERSENSITIVITY; FLUOROURACIL; HISTAMINE ANTAGONISTS; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PREMEDICATION; RETROSPECTIVE STUDIES;

EID: 80052705819     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-010-0170-6     Document Type: Article

References (19)

1. Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351. (Pubitemid 38702845)
2. Rosique-Robles D, Vicent Verge JM, Borras-Blasco J et al (2007) Successful desensitization protocol for hypersensitivity reactions caused by oxaliplatin. Int J Clin Pharmacol Ther 45:606-610. (Pubitemid 350047756)
3. Mis L, Fernando NH, Hurwitz HI et al (2005) Successful desensitization to oxaliplatin. Ann Pharmacother 39:966-969. (Pubitemid 40570680)
4. Newman Taylor AJ, Cullinan P, Lympany PA et al (1999) Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. Am J Respir Crit Care Med 160:435-438. (Pubitemid 29380654)
5. Zanotti KM, Rybicki LA, Kennedy AW et al (2001) Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19:3126-3129. (Pubitemid 32565451)
6. Kim BH, Bradley T, Tai J et al (2009) Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology 76:231-238.
7. Brandi G, Pantaleo MA, Galli C et al (2003) Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89:477-481. (Pubitemid 37026428)
8. Lenz G, Hacker UT, Kern W et al (2003) Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution. Anticancer Drugs 14:731-733. (Pubitemid 37357697)
9. Gowda A, Goel R, Berdzik J, et al (2004) Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology (Williston Park) 18:1671-1675 (discussion 1676, 1680, 1683- 1684).
10. Siu SW, Chan RT, Au GK (2006) Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 17:259- 261. (Pubitemid 43160115)
11. Markman M, Kennedy A, Webster K et al (1999) An effective and more convenient drug regimen for prophylaxis against paclitaxel- associated hypersensitivity reactions. J Cancer Res Clin Oncol 125:427-429. (Pubitemid 29287502)
12. Wrzesinski SH, McGurk ML, Donovan CT et al (2007) Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate. Anticancer Drugs 18:721-724. (Pubitemid 47343667)
13. Pagani M, Bonadonna P, Senna GE et al (2008) Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin. Int Arch Allergy Immunol 145:54-57. (Pubitemid 350275254)
14. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544. (Pubitemid 46733080)
15. Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019.
16. Goldberg RM, Sargent DJ, Morton RF et al (2006) Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 24: 3347-3353. (Pubitemid 46638888)
17. Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229-237. (Pubitemid 41095086)
18. Kitada N, Dan T, Takara K et al (2007) Oxaliplatin-induced hypersensitivity reaction displaying marked elevation of immunoglobulin E. J Oncol Pharm Pract 13:233-235.
19. Maindrault-Goebel F, Andre T, Tournigand C et al (2005) Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 41:2262-2267. (Pubitemid 41415602)